Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Long-Term Persistency And Costs Associated With The Use Of Iron Chelation Therapies In The Treatment Of Sickle Cell Disease Within Medicaid Programs., Edward P Armstrong, Grant H Skrepnek, Medha Sasane, Susan M Snodgrass, Samir K. Ballas
Long-Term Persistency And Costs Associated With The Use Of Iron Chelation Therapies In The Treatment Of Sickle Cell Disease Within Medicaid Programs., Edward P Armstrong, Grant H Skrepnek, Medha Sasane, Susan M Snodgrass, Samir K. Ballas
Department of Medicine Faculty Papers
OBJECTIVE: This retrospective study evaluated iron chelating therapy (ICT) discontinuation and costs in Sickle cell disease (SCD) Medicaid recipients using healthcare claims from 2006-2010.
METHODS: Patients with ≥1 SCD diagnosis claim, ≥2 claims for deferoxamine (DFO) or deferosirox (DFX), and continuous enrollment ≥6 months prior to and 18 months following ICT initiation were included. Outcomes included treatment discontinuation, persistence (i.e., refill gaps ≥6 weeks), and total healthcare costs.
RESULTS: The average age among 404 SCD patients meeting study inclusion criteria was 18.7 (±11.0) years, with 45.8% being males and 66.7% being Blacks. Switches or combinations from DFO at index occurred …